CTLA4 and cancer: Both preclinical and clinical data have shown that CTLA-4 and PD-L1 are key proteins in the regulation of immune checkpoints in cancer cells and their upregulation was shown to negatively affect T-cell response to cancer progression (Ribas 2012).